Merrimack Pharmaceuticals Valuation
| MACKDelisted Stock | USD 11.96 0.12 1.01% |
At this time, the firm appears to be overvalued. Merrimack Pharmaceuticals secures a last-minute Real Value of $10.33 per share. The latest price of the firm is $11.96. Our model forecasts the value of Merrimack Pharmaceuticals from analyzing the firm fundamentals such as Shares Owned By Insiders of 1.19 %, return on equity of -0.0112, and Current Valuation of (20.36 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Merrimack Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Merrimack Pharmaceuticals is based on 3 months time horizon. Increasing Merrimack Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Merrimack Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 11.96, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.96 | Real 10.33 | Hype 11.96 | Naive 12.17 |
The intrinsic value of Merrimack Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Merrimack Pharmaceuticals' stock price.
Estimating the potential upside or downside of Merrimack Pharmaceuticals helps investors to forecast how Merrimack stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Merrimack Pharmaceuticals more accurately as focusing exclusively on Merrimack Pharmaceuticals' fundamentals will not take into account other important factors: Merrimack Pharmaceuticals Total Value Analysis
Merrimack Pharmaceuticals is now forecasted to have valuation of (20.36 M) with market capitalization of 223.75 M, debt of 0, and cash on hands of 13.36 M. The negative valuation of Merrimack Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Merrimack Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(20.36 M) | 223.75 M | 0 | 13.36 M |
Merrimack Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Merrimack is to check how much profit was generated for every dollar of assets it reports. Merrimack Pharmaceuticals secures a negative usage of assets of -0.0107 %, losing $1.07E-4 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Merrimack Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Merrimack Pharmaceuticals Ownership Allocation
The market capitalization of Merrimack Pharmaceuticals is $223.75 Million. Over half of Merrimack Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Merrimack Pharmaceuticals Profitability Analysis
Net Loss for the year was (1.18 M) with loss before overhead, payroll, taxes, and interest of (9.1 M).Merrimack Pharmaceuticals Past Distributions to stockholders
About Merrimack Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Merrimack Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Merrimack Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Merrimack Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Merrimack Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Merrimack Pharmaceuticals. We calculate exposure to Merrimack Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Merrimack Pharmaceuticals's related companies.Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
A single share of Merrimack Pharmaceuticals represents a small ownership stake in the entity. As a stockholder of Merrimack, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Merrimack Pharmaceuticals Dividends Analysis For Valuation
Please note that Merrimack Pharmaceuticals has scaled down on payment of dividends at this time.
There are various types of dividends Merrimack Pharmaceuticals can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Merrimack shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Merrimack Pharmaceuticals directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Merrimack pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Merrimack Pharmaceuticals by the value of the dividends paid out.
Merrimack Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Merrimack Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 14.3 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |